

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (withdrawn): A method of selecting a neurogenic agent, comprising the steps of:

- (a) obtaining a stable neural progenitor cell line;
- (b) plating undifferentiated neural progenitor cells into an assay plate;
- (c) culturing the neural progenitor cells in a serum-free, mitogen-free medium;
- (d) exposing the neural progenitor cells to a test agent; and
- (e) measuring a change in the number of neurons.

Claim 2 (withdrawn): The method of claim 1, wherein the neural progenitor cell line is derived from mammalian CNS.

Claim 3 (withdrawn): The method of claim 1, wherein the neural progenitor cell line is derived from human CNS.

Claim 4 (withdrawn): The method of claim 1, wherein the neural progenitor cell line is derived from human hippocampus.

Claim 5 (withdrawn): The method of claim 1, wherein the neural progenitor cell line is derived from human subventricular zone.

Claim 6 (withdrawn): The method of claim 1, wherein the neural progenitor cell line is derived from mammalian pluripotent or totipotent stem cells.

Claim 7 (withdrawn): The method of claim 1, wherein the neural progenitor cell line is capable of differentiating into neurons and glia.

Claim 8 (withdrawn): The method of claim 1, wherein the neural progenitor cell line is capable of differentiating into neurons.

Claim 9 (withdrawn): The method of claim 1, wherein the test agent is a fused imidazole, as described in Structure Formula 1.

Claim 10 (withdrawn): The method of claim 1, wherein the test agent is a aminopyrimidine, as described in Structure Formula 2.

Claim 11 (withdrawn): The method of claim 1, wherein the test agent is a nicotinamide, as described in Structure Formula 3.

Claim 12 (withdrawn): The method of claim 1, wherein the test agent is an aminomethyl phenoxypiperidine, as described in Structure Formula 4.

Claim 13 (withdrawn): The method of claim 1, wherein the test agent is an aryloxypiperidine, as described in Structure Formula 5.

Claim 14 (original): A method for treating neurodegenerative and neuropsychiatric disorders comprising the step of administering a fused imidazole, as described in Structure Formula 1, to a patient in need thereof.

Claim 15 (withdrawn): A method for treating neurodegenerative and neuropsychiatric disorders comprising the step of administering an aminopyrimidine, as described in Structure Formula 2, to a patient in need thereof.

Claim 16 (withdrawn): A method for treating neurodegenerative and neuropsychiatric disorders comprising the step of administering a nicotinamide, as described in Structure Formula 3, to a patient in need thereof.

Claim 17 (withdrawn): A method for treating neurodegenerative and neuropsychiatric disorders comprising the step of administering an aminomethyl phenoxypiperidine, as described in Structure Formula 4, to a patient in need thereof.

Claim 18 (withdrawn): A method for treating neurodegenerative and neuropsychiatric disorders comprising the step of administering an aryloxypiperidine, as described in Structure Formula 5, to a patient in need thereof.

Claim 19 (new): A method for treating neurodegenerative and neuropsychiatric disorders comprising the step of administering to an individual in need thereof a neurogenic agent sufficient to increase the number of neurons in said individual.

Claim 20 (new): The method of Claim 19, wherein the individual is an adult human.